332 related articles for article (PubMed ID: 29465589)
1. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
Geng TT; Xu X; Huang M
Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
3. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
[No Abstract] [Full Text] [Related]
7. Bloodstream Infections due to Carbapenem-Resistant
Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H
Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.
Tian Y; Zhang Q; Wen L; Chen J
Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study.
Mouloudi E; Massa E; Piperidou M; Papadopoulos S; Iosifidis E; Roilides I; Theodoridou T; Kydona C; Fouzas I; Imvrios G; Papanikolaou V; Gritsi-Gerogianni N
Transplant Proc; 2014 Nov; 46(9):3219-21. PubMed ID: 25420864
[TBL] [Abstract][Full Text] [Related]
10. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China.
Li Y; Li J; Hu T; Hu J; Song N; Zhang Y; Chen Y
Antimicrob Resist Infect Control; 2020 Jun; 9(1):79. PubMed ID: 32487221
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
[No Abstract] [Full Text] [Related]
12. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro.
Zhang J; Yu L; Fu Y; Zhao Y; Wang Y; Zhao J; Guo Y; Li C; Zhang X
Ann Palliat Med; 2019 Nov; 8(5):622-631. PubMed ID: 31735038
[TBL] [Abstract][Full Text] [Related]
13. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Vieceli T; Henrique LR; Rech TH; Zavascki AP
J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
[TBL] [Abstract][Full Text] [Related]
14. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae infections are associated with higher mortality compared to carbapenem-susceptible K. pneumoniae infections in the intensive care unit: a retrospective cohort study.
Yao Y; Zha Z; Li L; Tan H; Pi J; You C; Liu B
J Hosp Infect; 2024 Jun; 148():30-38. PubMed ID: 38513959
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of carbapenem-resistant
Wang Y; Lei H; Zhang Y; Yang Q; Wang Y; Wang J; Xu C; Yu J; Zhou L; Kang X; Cui L
Antimicrob Resist Infect Control; 2018; 7():66. PubMed ID: 29942492
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
[TBL] [Abstract][Full Text] [Related]
18. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.
Micozzi A; Gentile G; Minotti C; Cartoni C; Capria S; Ballarò D; Santilli S; Pacetti E; Grammatico S; Bucaneve G; Foà R
BMC Infect Dis; 2017 Mar; 17(1):203. PubMed ID: 28283020
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
